Amy Wheeler
Family · Atlanta, GANPI 1013253103
Payments from drug & device makers
Across 124 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$505
- Johnson & Johnson$383
- Ardelyx, Inc.$355
- Regeneron Healthcare Solutions, Inc.$331
- QOL Medical, LLC$263
- Madrigal Pharmaceuticals$257
- plus $738 from 13 others
What the payments were for
- Food & beverage$2,833100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $505 |
| Johnson & Johnson | 9 | $383 |
| Ardelyx, Inc. | 16 | $355 |
| Regeneron Healthcare Solutions, Inc. | 9 | $331 |
| QOL Medical, LLC | 10 | $263 |
| Madrigal Pharmaceuticals | 13 | $257 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $163 |
| Gilead | 5 | $101 |
| Atricure, Inc. | 1 | $93 |
| Sanofi | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Redhill Biopharma Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Pfizer | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,833 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 14 | $29,291 |
| Dexlansoprazole DrDexlansoprazole | 22 | $7,502 |
| MovantikNaloxegol Oxalate | 13 | $5,126 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 193 | $3,307 |
| Colestipol Hcl | 41 | $2,744 |
| Budesonide DrBudesonide | 16 | $1,948 |
| Pantoprazole Sodium | 171 | $1,729 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 22 | $1,353 |
| Famotidine | 95 | $1,063 |
| Sucralfate | 44 | $1,019 |
| Omeprazole | 65 | $808 |
| Ondansetron OdtOndansetron | 42 | $534 |
| Esomeprazole Magnesium | 18 | $509 |
| Metronidazole | 18 | $139 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $505 | $29,29114 claims |
| Redhill Biopharma Inc.Movantik | $19 | $5,12613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Atlanta
- Stacey TatroeAtlanta$38K
- Brandy HughesAtlanta$29K
- Cecile MartinAtlanta$23K
- Terri CowanAtlanta$21K
- Brandi Pinckney-GreeneAtlanta$18K
- Michelle SarievAtlanta$18K
- Christopher VreelandAtlanta$17K
- Angelica MillerAtlanta$15K
- Andrea Jefferson SaboorAtlanta$14K
- Allie McAllisterMarietta$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.